Article Text

Download PDFPDF
Original research
Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis
  1. Rohit Loomba1,2,
  2. Daniel Q. Huang2,3,4,
  3. Arun J Sanyal5,
  4. Quentin Mark Anstee6,
  5. Michael Trauner7,
  6. Eric J Lawitz8,
  7. Dora Ding9,
  8. Lily Ma9,
  9. Catherine Jia9,
  10. Andrew Billin9,
  11. Ryan S Huss9,
  12. Chuhan Chung9,
  13. Zachary Goodman10,
  14. Vincent Wai-Sun Wong11,
  15. Takeshi Okanoue12,
  16. Manuel Romero-Gómez13,
  17. Manal F Abdelmalek14,
  18. Andrew Muir15,
  19. Nezam Afdhal16,
  20. Jaime Bosch17,
  21. Stephen Harrison18,19,
  22. Zobair M Younossi20,
  23. Robert P Myers9
  1. 1Division of Epidemiology, Department of Family Medicine and Public Health, University of California at San Diego, University of California at San Diego, San Diego, California, USA
  2. 2NAFLD Research Center, University of California San Diego, La Jolla, California, USA
  3. 3Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore
  4. 4Division of Gastroenterology and Hepatology, Department of Medicine, National University Health System, Singapore
  5. 5Division of Gastroenterology, Department of Internal Medicine, Virginia Commonwealth University School of Medicine, Richmond, Virginia, USA
  6. 6Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK
  7. 7Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria
  8. 8Texas Liver Institute, UT Health San Antonio, San Antonio, Texas, USA
  9. 9Gilead Sciences Inc, Foster City, California, USA
  10. 10Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, Virginia, USA
  11. 11Department of Medicine and Therapeutics, Chinese University of Hong Kong, Hong Kong, China
  12. 12Hepatology Center, Saiseikai Suita Hospital, Suita, Japan
  13. 13Unit for The Clinical Management of Digestive Diseases and CIBERehd, Hospital Universitario de Valme, Sevilla, Spain
  14. 14Duke University, Durham, North Carolina, USA
  15. 15Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
  16. 16Division of Gastroenterology and Hepatology, Beth Israel Medical Center, Harvard University Medical School, Boston, Massachusetts, USA
  17. 17Inselspital Universitätsspital Bern, Bern, Switzerland
  18. 18Radcliffe Department of Medicine, University of Oxford, Oxford, UK
  19. 19Pinnacle Clinical Research, San Antonio, Texas, USA
  20. 20Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, Virginia, USA
  1. Correspondence to Professor Rohit Loomba, University of California San Diego, La Jolla, California, USA; roloomba{at}ucsd.edu

Abstract

Objective In retrospective studies, liver stiffness (LS) by vibration-controlled transient elastography (VCTE) is associated with the risk of liver decompensation in patients with non-alcoholic steatohepatitis (NASH), but prospective data in biopsy-confirmed cohorts with advanced fibrosis are limited. We aimed to establish thresholds for LS by VCTE that predict progression to cirrhosis among patients with bridging fibrosis and hepatic decompensation among patients with cirrhosis due to NASH.

Design We used data from four randomised placebo-controlled trials of selonsertib and simtuzumab in participants with advanced fibrosis (F3–F4). The trials were discontinued due to lack of efficacy. Liver fibrosis was staged centrally at baseline and week 48 (selonsertib study) or week 96 (simtuzumab study). Associations between LS by VCTE with disease progression were determined using Cox proportional hazards regression analysis.

Results Progression to cirrhosis occurred in 16% (103/664) of participants with bridging fibrosis and adjudicated liver-related events occurred in 4% (27/734) of participants with baseline cirrhosis. The optimal baseline LS thresholds were ≥16.6 kPa for predicting progression to cirrhosis, and ≥30.7 kPa for predicting liver-related events. Baseline LS ≥16.6 kPa (adjusted HR 3.99; 95% CI 2.66 to 5.98, p<0.0001) and a ≥5 kPa (and ≥20%) increase (adjusted HR 1.98; 95% CI 1.20 to 3.26, p=0.008) were independent predictors of progression to cirrhosis in participants with bridging fibrosis, while baseline LS ≥30.7 kPa (adjusted HR 10.13, 95% CI 4.38 to 23.41, p<0.0001) predicted liver-related events in participants with cirrhosis.

Conclusion The LS thresholds identified in this study may be useful for risk stratification of NASH patients with advanced fibrosis.

  • cirrhosis
  • fibrosis
  • nonalcoholic steatohepatitis

Data availability statement

No data are available.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Data availability statement

No data are available.

View Full Text

Footnotes

  • Twitter @mromerogomez

  • Contributors Study design: RL and RPM. Data acquisition: RL, DD, CJ, AB, RSH, CC, ZG and RPM. Data analysis: RL, DH, DD, LM, CJ and RPM. Data interpretation and review/revision of the manuscript: all authors. Study concept and study supervision: RL and RPM. Writing of first draft: DH and RL. All authors approved the final draft of the manuscript as well as the authorship list. Gurantor of article: RL.

  • Funding This study was funded by Gilead Sciences (NCT03053050; NCT03053063; NCT01672866; NCT01672879)

  • Competing interests RL receives funding support from NIAAA (U01AA029019), NIEHS (5P42ES010337), NCATS (5UL1TR001442), NIDDK (U01DK130190, U01DK061734, R01DK106419, P30DK120515, R01DK121378, R01DK124318), NHLBI (P01HL147835), and DOD PRCRP (W81XWH-18-2-0026). RL serves as a consultant to Aardvark Therapeutics, Altimmune, Anylam/Regeneron, Amgen, Arrowhead Pharmaceuticals, AstraZeneca, Bristol-Myer Squibb, CohBar, Eli Lilly, Galmed, Gilead, Glympse bio, Hightide, Inipharma, Intercept, Inventiva, Ionis, Janssen, Madrigal, Metacrine, NGM Biopharmaceuticals, Novartis, Novo Nordisk, Merck, Pfizer, Sagimet, Theratechnologies, 89 bio, Terns Pharmaceuticals and Viking Therapeutics. In addition his institutions received research grants from Arrowhead Pharmaceuticals, Astrazeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly, Galectin Therapeutics, Galmed Pharmaceuticals, Gilead, Intercept, Hanmi, Intercept, Inventiva, Ionis, Janssen, Madrigal Pharmaceuticals, Merck, NGM Biopharmaceuticals, Novo Nordisk, Merck, Pfizer, Sonic Incytes and Terns Pharmaceuticals. Co-founder of LipoNexus Inc. DH receives funding support from Singapore Ministry of Health’s National Medical Research Council under its NMRC Research Training Fellowship (MOH-000595-01). In addition, he has served as an advisory board member for Eisai. MFA receives funding support from NIDDK (U01DK130177, U01DK061713, R01DK12137), NCI (UG1CA242643) and DOD (W81XWH2010514). MFA serves as a consultant/advisor to Bristol-Myer Squibb, CohBar, Inventiva, Madrigal, NGM Biopharmaceuticals, Novo Nordisk, Theratechnologies, 89 Bio, Somologics, and Hanmi Pharmaceuticals. In addition, her institutions received research grants from Allergan, Boehringer-Ingelheim, Bristol-Myers Squibb, Enyo, Enanta, Durect, Galectin Therapeutics, Gilead, Galmed, Intercept, Hanmi, Inventiva, Madrigal Pharmaceuticals, NGM Biopharmaceuticals, Novartis, Novo Nordisk, Poxel, TARGET PharmaSolutions, Celgene, Genentech. and Viking Pharmaceuticals. QMA is funded by the LITMUS (Liver Investigation: Testing Marker Utility in Steatohepatitis) consortium funded by the Innovative Medicines Initiative (IMI2) Program of the European Union under Grant Agreement 777377; this Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. He reports Research Grant Funding from Allergan/Tobira, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Glympse Bio, Intercept, Novartis Pharma AG, Pfizer Ltd; Consultancy from 89Bio, Abbvie/Allergan, Altimentiv, Altimmune, AstraZeneca, Axcella, Blade, BMS, BNN Cardio, Boehringer Ingelheim, Cirius, CymaBay, EcoR1, E3Bio, Eli Lilly & Company Ltd., Galmed, Genentech, Genfit SA, Gilead, Grunthal, HistoIndex, Indalo, Intercept Pharma Europe Ltd., Inventiva, IQVIA, Janssen, Johnson & Johnson, Madrigal, MedImmune, Medpace, Merck, Metacrine, NGMBio, North Sea Therapeutics, Novartis, Novo Nordisk A/S, PathAI, Pfizer, Poxel, ProSciento, Raptor Pharma, Roche, Servier, Shionogi, Terns, The Medicines Company, Viking Therapeutics; Speaker fees from Abbott Laboratories, Allergan/Tobira, BMS, Clinical Care Options, Falk, Fishawack, Genfit SA, Gilead, Integritas Communications, Kenes, Medscape; and Royalties from Elsevier. DD, LM, CJ, AB, RSH, CC and RPM are employees and shareholders of Gilead Sciences. VW served as a consultant or advisory board member for AbbVie, Boehringer Ingelheim, Echosens, Gilead Sciences, Inventiva, Merck, Novo Nordisk, Pfizer, ProSciento, Sagimet Biosciences, and TARGET PharmaSolutions; and a speaker for Abbott, AbbVie, Echosens, Gilead Sciences, Novo Nordisk. He has received a research grant from Gilead Sciences, and was a co-founder of Illuminatio Medical Technology Limited. JB was a consultant for Gilead Sciences, Actelion and Surrozen.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.